Bevacizumab is active as a single agent against recurrent malignant gliomas

Anticancer Research

Volumn 30, Issue 2, 2010, Pages 609-611

  Agha, Caroline A ^c   Ibrahim, Saman ^c   Hassan, Ahmed ^c   Elias, Dean A ^c   Fathallah Shaykh, Hassan M ^a,b  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Monoclonal antibody; Progression free survival; Radiological response; VEGF

Indexed keywords

BEVACIZUMAB; DOXORUBICIN; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLIOBLASTOMA; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; PROTEINURIA; RECURRENT CANCER; SALVAGE THERAPY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; DACARBAZINE; DOXORUBICIN; FEMALE; GLIOMA; HUMANS; LOMUSTINE; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROCARBAZINE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; VINCRISTINE;

EID: 77950548381     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Fabel K, Dietrich J, Hau P, Wismeth C, Winner B, Przywara S, Steinbrecher A, Ullrich W and Bogdahn U: Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer 92: 1936-1942, 2001.
2. Hau P, Fabre M, Baumgart U, Rümmele P, Grauer O, Bock A, Dietmaier C, Dietrich J, Dudel C, Hübner F, Jauch T, Drechsel E, Kleiter I, Wismeth C, Zellner A, Brawanski A, Steinbrecher A, Marienhagen J and Bogdahn U: Pegylated liposomal doxorubicin efficacy in patients with recurrent high-grade glioma. Cancer 100: 1199-1207, 2004.
3. Macdonald DR, Cascino TL, Schold SC Jr and Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277-1280, 1990.
4. Kaus MR, Warfield SK, Nabavi A, Black PM, Jolesz FA and Kikinis R: Automated segmentation of MR images of brain tumors. Radiology 218: 586-591, 2001.
5. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH and Friedman HS: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13: 1253-1259, 2007.
6. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH and Friedman HS: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25: 4722-4729, 2007.
7. Pope WB, Lai A, Nghiemphu P, Mischel P and Cloughesy TF: MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66: 1258-1260, 2007.
8. Guiu S, Taillibert S, Chinot O, Taillandier L, Dietrich PY, Maire JP, Guillamo JS, Guiu B, Catry-Thomas I, Thiebaut A, Cartalat-Carel S, Deville C, Fumoleau P, Desjardins A, Xuan KH and Chauffert B: Bevacizumab/irinotecan. An active treatment for recurrent high-grade gliomas: Preliminary results of an ANOCEF Multicenter Study. Rev Neurol 164: 588-594, 2008.
9. Bokstein F, Shpigel S and Blumenthal DT: Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer 112: 2267-2273, 2008.
10. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S and Wen PY: Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70: 779-787, 2008.
11. Sathornsumetee S, Cao Y, Marcello JE, Herndon JE 2nd, McLendon RE, Desjardins A, Friedman HS, Dewhirst MW, Vredenburgh JJ and Rich JN: Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 26: 271-278, 2008.
12. Chamberlain MC, Wei-Tsao DD, Blumenthal DT and Glantz MJ: Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma. Cancer 112: 2038-2045, 2008.
13. Prados MD, Lamborn K, Yung WK, Jaeckle K, Robins HI, Mehta M, Fine HA, Wen PY, Cloughesy T, Chang S, Nicholas MK, Schiff D, Greenberg H, Junck L, Fink K, Hess K, Kuhn J and North American Brain Tumor Consortium: A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol 8: 189-193, 2006.